Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ApTOLL Infusion vs Bolus in Healthy Volunteers
NCT05569720Phase 1Completed
- Sponsor
- aptaTargets
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aptoll in ischemic stroke, sponsored by aptaTargets. Primary endpoint: Adverse Events. Started Apr 2022; status: completed.
02
Drugs
aptoll
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05569720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569720.